Nasdaq
$1.41▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $115.5MShares out 82.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 10.16After-hours26.10.17 05:316-K/AKey event#●●●#●●●
NERVGEN PHARMA CORP.
NervGen Pharma has restated its interim financial statements for the three and six months ended June 30, 2026, due to valuation errors regarding stock options and warrant derivative liabilities. The company confirmed that these adjustments do not impact its cash position, cash flow, or liquidity. Additionally, the company identified material weaknesses in its internal control over financial reporting and is currently implementing remediation plans.…more
$1.41+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.16After-hours26.10.17 05:3040-F/AEarnings
NERVGEN PHARMA CORP.
NervGen Pharma filed an amended Form 40-F/A to restate its financial statements for the fiscal year 2025. The company reported a net loss of 44.21 million CAD for 2025, and the material uncertainty regarding its going concern status has been resolved following a 60 million USD public offering completed in May 2026.…more
$1.41+0.00%vs prev closeView filingShare - 9.25After-hours26.09.26 05:306-KKey event
NERVGEN PHARMA CORP.
NervGen Pharma announced that its previously issued financial statements for 2024, 2025, and the second quarter of 2026 should no longer be relied upon due to non-cash valuation errors regarding stock options and derivative warrant liabilities. The company intends to restate these financial statements, noting that the adjustments will have no impact on its cash position, cash flow, or liquidity.…more
$1.41+0.00%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.12Pre-market26.10.12 20:15#●●●#●●●
NervGen Initiates Phase 3 Trial for Spinal Cord Injury Drug NVG-291
NervGen has dosed the first participant in its Phase 3 registrational study for NVG-291, a treatment for chronic spinal cord injury. Topline data is expected in the first half of 2028, though the clinical development remains in progress.…more
$1.41+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.25After-hours26.09.26 05:30
●●●●●●●● ●●●●● ●●●●●●
NervGen announced it will restate its previous financial statements to correct non-cash accounting adjustments. These revisions do not impact the company's cash position or ongoing business operations.…more
$1.41+0.00%vs prev close - 9.9Pre-market26.09.09 20:30
●●●●●●●● ●●●●● ●●●●●●
NervGen will host its inaugural R&D Day on September 30, 2026, to provide an in-depth review of its lead candidate NVG-291 and the upcoming Phase 3 RESTORE study. The event will feature presentations from leading experts to discuss the clinical data and therapeutic potential of the company's neuroreparative pipeline.…more
$1.41+0.00%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report